Skip to content

Efficacy and safety of ciprofol versus propofol for ophthalmic general anaesthesia in elderly patients: a randomized, doubleblind, controlled study

Efficacy and safety of ciprofol versus propofol for ophthalmic general anaesthesia in elderly patients: a randomized, doubleblind, controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095257
Enrollment
Unknown
Registered
2025-01-03
Start date
2025-01-17
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group ciprofol group (group C):During the induction period, ciprofol was slowly injected 0.3mg/kg intravenously
Control group propofol group (group P):2mg/kg propofol was slowly injected intravenously during the induction period.

Sponsors

Hebei Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with ASA grade I-III; 2.>=60 years old; 3.BMI18.5 ~ 29.9kg/m^2; 4.Patients undergoing general anesthesia with laryngeal mask for ophthalmology;

Exclusion criteria

Exclusion criteria: 1. There are contraindications of laryngeal mask application such as fullness of stomach, abnormal oropharyngeal structure and gastroesophageal reflux disease; 2. Suffering from severe cardiovascular and cerebrovascular diseases; 3. Patients with severe impairment of liver and kidney function, mental illness or cognitive dysfunction; 4. Patients who have been taking sedatives and analgesics for a long time and are allergic to the study drug; 5. Patients who expect surgery time to be too long (more than 4 hours) or too short (less than 30 minutes); 6. Hypertensive patients with drug control >=160/100mmHg;

Design outcomes

Primary

MeasureTime frame
Hemodynamics(SBP?DBP?MAP?HR);

Secondary

MeasureTime frame
Depth of anesthesia;Incidence of adverse reactions;Quality of recovery (time to recovery and restlessness during recovery and PACU residence time);Cognitive function;

Countries

China

Contacts

Public ContactFang Li

Hebei Eye Hospital

lifangxt@163.com+86 319 3237043

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026